中文

沃森生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥0.44B-4.0%
Gross profit¥0.30B
Operating income¥0.13B
Net income¥0.11B
Gross margin68.5%Net margin 25.8%
Revenue Q/Q-36.5%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.14B31.5%
R&D¥0.04B9.9%
SG&A¥0.21B48.4%
Tax & other¥0.02B3.7%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

盈康生命宋城演艺南方泵业汤臣倍健*ST香雪天舟文化睿智医药世纪瑞尔昌红科技*ST动力科泰电源瑞凌股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies